短暂性掌跖角化病与大疱性类天疱疮临床及免疫学特征的关联
这项病例系列研究纳入2015年1月1日至2017年12月31日单中心治疗的6例出现获得性短暂性掌跖角化病(PPK)的大疱性类天疱疮(BP)患者,分析其临床与免疫学特征、治疗及结局。PPK在BP诊断后平均6.2个月出现,此时BP未控制,加用全身免疫抑制治疗后PPK平均4.3个月愈合,4/6例BP临床缓解;PPK出现时疱液中IL-1β、IL-17A、IL-17F和IL-22表达增强。作者认为短暂性PPK可能是严重、治疗抵抗性BP的临床标志。
要点
- 6例BP患者出现短暂性PPK,平均年龄72岁,5女1男。
- PPK出现时BP未控制,平均BPDAI评分57,平均抗BP180抗体滴度122 U/mL。
- 加用免疫抑制治疗后PPK平均4.3个月愈合,4/6例BP临床缓解。
核心结论
- 短暂性PPK出现在BP长期活动并反复复发之后,为暂时性,在加用免疫抑制治疗控制BP后愈合。
- PPK出现时疱液中特定细胞因子组合表达增强,可能支持类似银屑病中所见的角质形成细胞增殖。
- 短暂性PPK可能代表严重、治疗抵抗性BP的临床标志。
研究设计与样本
- 病例系列研究,纳入2015年1月1日至2017年12月31日单中心治疗的6例出现获得性短暂性PPK的BP患者。
- 主要结局指标为BP临床与免疫学活动度、PPK出现前后所接受的治疗及患者结局。
主要发现
- 6例患者中5女1男,平均年龄72岁;基线时全部患者为泛发性多发性大疱性BP,血清抗BP180抗体升高(均值130 U/mL,范围73-150),仅1例抗BP230抗体升高。
- PPK在BP诊断后平均6.2个月(范围2-12)出现;出现时BP未控制,平均BPDAI评分57(范围34-105),平均抗BP180抗体滴度122 U/mL(范围81-150)。
- 加用全身免疫抑制治疗后,PPK平均4.3个月(范围2-9)逐渐愈合,4/6例患者BP临床缓解。
- 未发现PPK发生与抗BP180/230抗体谱之间的关系;PPK出现时疱液IL-1β水平远高于无PPK时采集的疱液,且疱液中IL-17A、IL-17F和IL-22表达增强。
临床怎么用
- 作者认为短暂性PPK可能是严重、治疗抵抗性BP的临床标志。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Development of transient palmoplantar keratoderma (PPK) with bullous pemphigoid (BP) has only been described in 2 isolated case reports. The clinical significance and the pathophysiologic mechanisms of this association are unknown. OBJECTIVE: To examine the clinical characteristics and immunological profile of patients with BP who develop transient PPK and analyze therapeutic options and outcomes. DESIGN, SETTING, AND PARTICIPANTS: In this case series, patients with BP who developed acquired, transient PPK, and were treated at a single institution from January 1, 2015, through December 31, 2017, were studied. MAIN OUTCOMES AND MEASURES: Clinical and immunological activity of BP, treatment administrated before and after PPK appearance, and patient outcomes. RESULTS: Six patients with BP and transient PPK were identified and included in the study. There were 5 women and 1 man with a mean age of 72 years. At baseline, all patients had a generalized, multibullous BP and high serum anti-BP180 antibodies (mean, 130 U/mL; range, 73-150), whereas anti-BP230 antibodies were elevated in only 1 case. The PPK appeared a mean 6.2 (range, 2-12) months after BP diagnosis, following a prolonged period of disease activity with recurrent flares. When the PPK occurred, BP was uncontrolled on therapy (mean Bullous Pemphigoid Disease Activity Index [BPDAI] score, 57; range, 34-105; mean anti-BP180 antibodies titer, 122 U/mL; range, 81-150). On administration of additional systemic immunosuppressive therapies, the PPK healed progressively in a mean 4.3 months (range, 2-9), along with BP clinical remission in 4 of 6 patients. No relationship was found between PPK occurrence and anti-BP180/230 antibodies profiles. In contrast, blister fluids collected at the time of PPK displayed a much higher level of interleukin 1β (IL-1β) compared with those collected in the absence of PKK. Expression of IL-17A, IL-17F, and IL-22 was also enhanced in the blister fluid of patients with BP who had PPK. CONCLUSIONS AND RELEVANCE: To our knowledge, this is the first report of 6 cases of BP with transient PPK with extensive immunological investigation. The PPK appeared after a prolonged period of clinical BP activity punctuated with recurrent relapses, was transient, and healed after BP control with additional immunosuppressive therapy. Enhanced expression of a particular cytokine panel in the blister fluid at time of PPK could support keratinocyte proliferation as described in patients with psoriasis. Transient PPK could represent a clinical marker of severe, treatment-resistant BP.
引用
- Duretz C, Antonicelli F, Muller C, et al. Association of Transient Palmoplantar Keratoderma With Clinical and Immunologic Characteristics of Bullous Pemphigoid. JAMA Dermatol. 2019. PMID: 30484821. doi:10.1001/jamadermatol.2018.4084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。